The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Harnessing albumin as a carrier for cancer therapies
Open accessAbstract
Serum albumin, a natural ligand carrier that is highly concentrated and long‐circulating in the blood, has shown remarkable promise as a carrier for anti‐cancer agents. Albumin is able to prolong the circulation half‐life of otherwise rapidly cleared drugs and, importantly, promote their accumulation within tumors. The applications for using albumin as a cancer drug carrier are broad and include both traditional cancer chemotherapeutics and new classes of biologics. Strategies for leveraging albumin for drug delivery can be classified broadly into exogenous and in situ binding formulations that utilize covalent attachment, non‐covalent association, or encapsulation in albumin‐based nanoparticles. These methods have shown remarkable preclinical and clinical successes that are examined in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Carter, D. C., & Ho, J. X. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60640-3 · Cited by 3,187
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683
Molecular aspects of ligand binding to serum albumin.
Kragh-Hansen, U. (1981) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06849-8 · Cited by 1,544
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
Curry, S., Mandelkow, H., Brick, P., & Franks, N. (1998) · Nature Structural Biology · doi:10.1038/1869 · Cited by 1,377
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Chen, Q., Feng, L., Liu, J., Zhu, W., Dong, Z., Wu, Y., & Liu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201601902 · Cited by 1,034
Caveolae: From Cell Biology to Animal Physiology
Razani, B., Woodman, S. E., & Lisanti, M. P. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.431 · Cited by 987
Structure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
Kamphorst, J. J., Nofal, M., Commisso, C., Hackett, S. R., Lu, W., Grabocka, E., Vander Heiden, M. G., Miller, G., Drebin, J. A., Bar-Sagi, D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2211 · Cited by 893
Practical Aspects of the Ligand-Binding and Enzymatic Properties of Human Serum Albumin.
Kragh-Hansen, U., Chuang, V. T. G., & Otagiri, M. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.695 · Cited by 892
Impact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819
Sheng, Z., Hu, D., Zheng, M., Zhao, P., Liu, H., Gao, D., Gong, P., Gao, G., Zhang, P., Ma, Y., et al. (2014) · ACS Nano · doi:10.1021/nn5062386 · Cited by 719
Albumin-based drug delivery: harnessing nature to cure disease
Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016) · Molecular and Cellular Therapies · doi:10.1186/s40591-016-0048-8 · Cited by 683
Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., & Frejd, F. Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.014 · Cited by 651
Unraveling the mysteries of serum albumin—more than just a serum protein
Merlot, A. M., Kalinowski, D. S., & Richardson, D. R. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00299 · Cited by 641
Human serum albumin, systemic inflammation, and cirrhosis
Arroyo, V., García-Martinez, R., & Salvatella, X. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.012 · Cited by 560
Lin, T., Zhao, P., Jiang, Y., Tang, Y., Jin, H., Pan, Z., He, H., Yang, V. C., & Huang, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b04268 · Cited by 527
Caveolin-1 in oncogenic transformation, cancer, and metastasis
Williams, T. M., & Lisanti, M. P. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00458.2004 · Cited by 511
Albumin as a versatile platform for drug half-life extension
Sleep, D., Cameron, J., & Evans, L. R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.023 · Cited by 485
MS-325: albumin-targeted contrast agent for MR angiography.
Lauffer, R. B., Parmelee, D. J., Dunham, S. U., Ouellet, H. S., Dolan, R. P., Witte, S., McMurry, T. J., & Walovitch, R. C. (1998) · Radiology · doi:10.1148/radiology.207.2.9577506 · Cited by 457
Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery
Zheng, Y.-R., Suntharalingam, K., Johnstone, T. C., Yoo, H., Lin, W., Brooks, J. G., & Lippard, S. J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5038269 · Cited by 440
Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure
Evans, T. W. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.16.s5.2.x · Cited by 409
Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy
Lee, S. H., Heng, D., Ng, W. K., Chan, H.-K., & Tan, R. B. H. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.10.012 · Cited by 405
Desai, N., Trieu, V., Damascelli, B., & Soon-Shiong, P. (2009) · Translational Oncology · doi:10.1593/tlo.09109 · Cited by 396
Renal albumin absorption in physiology and pathology
Birn, H., & Christensen, E. I. (2006) · Kidney International · doi:10.1038/sj.ki.5000141 · Cited by 381
Beyond antigens and adjuvants: formulating future vaccines
Moyer, T. J., Zmolek, A. C., & Irvine, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81083 · Cited by 374
Miller, M. A., Gadde, S., Pfirschke, C., Engblom, C., Sprachman, M. M., Kohler, R. H., Yang, K. S., Laughney, A. M., Wojtkiewicz, G., Kamaly, N., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac6522 · Cited by 347
Caveolae-deficient Endothelial Cells Show Defects in the Uptake and Transport of Albumin in Vivo
Schubert, W., Frank, P. G., Razani, B., Park, D. S., Chow, C.-W., & Lisanti, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100613200 · Cited by 337
A clinical update of using albumin as a drug vehicle — A commentary
Kratz, F. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.013 · Cited by 334
Schnitzer, J. E., & Oh, P. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37571-3 · Cited by 324
Cubilin is an albumin binding protein important for renal tubular albumin reabsorption
Birn, H., Fyfe, J. C., Jacobsen, C., Mounier, F., Verroust, P. J., Ørskov, H., Willnow, T. E., Moestrup, S. K., & Christensen, E. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8862 · Cited by 320
Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
Zhu, G., Lynn, G. M., Jacobson, O., Chen, K., Liu, Y., Zhang, H., Ma, Y., Zhang, F., Tian, R., Ni, Q., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02191-y · Cited by 315
Cubilin Is Essential for Albumin Reabsorption in the Renal Proximal Tubule
Amsellem, S., Gburek, J., Hamard, G., Nielsen, R., Willnow, T. E., Devuyst, O., Nexo, E., Verroust, P. J., Christensen, E. I., & Kozyraki, R. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010050492 · Cited by 314
Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Stewart, J. C. M., Hartung, G., Maier-Borst, W., & Heene, D. L. (1997) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(97)00015-2 · Cited by 305
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Michaelis, K., Hoffmann, M. M., Dreis, S., Herbert, E., Alyautdin, R. N., Michaelis, M., Kreuter, J., & Langer, K. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097139 · Cited by 303
Ersoy, H., & Rybicki, F. J. (2007) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21135 · Cited by 283
Oncogenic Ras and its role in tumor cell invasion and metastasis
Campbell, P. M., & Der, C. J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.015 · Cited by 275
Kratz, F., Warnecke, A., Scheuermann, K., Stockmar, C., Schwab, J., Lazar, P., Drückes, P., Esser, N., Drevs, J., Rognan, D., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020276c · Cited by 275
Ganson, N. J., Povsic, T. J., Sullenger, B. A., Alexander, J. H., Zelenkofske, S. L., Sailstad, J. M., Rusconi, C. P., & Hershfield, M. S. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.034 · Cited by 273
Zu (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s12918 · Cited by 272
Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244
Engineering of a femtomolar affinity binding protein to human serum albumin
Jonsson, A., Dogan, J., Herne, N., Abrahmsen, L., & Nygren, P.-A. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn028 · Cited by 242
Mansour, A. M., Drevs, J., Esser, N., Hamada, F. M. A., Badary, O. A., Unger, C., Fichtner, I., & Kratz, F. (2003) · PubMed · Cited by 239
A Portable Albumin Binder from a DNA‐Encoded Chemical Library
Dumelin, C. E., Trüssel, S., Buller, F., Trachsel, E., Bootz, F., Zhang, Y., Mannocci, L., Beck, S. C., Drumea‐Mirancea, M., Seeliger, M. W., et al. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200704936 · Cited by 233
Chen, Q., Liang, C., Wang, X., He, J., Li, Y., & Liu, Z. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.07.062 · Cited by 219
Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells
Steinhauser, I., Spänkuch, B., Strebhardt, K., & Langer, K. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.05.016 · Cited by 216
Tahir, S. A., Yang, G., Ebara, S., Timme, T. L., Satoh, T., Li, L., Goltsov, A. A., Ittmann, M., Morrisett, J. D., & Thompson, T. C. (2001) · PubMed · Cited by 215
Nanoparticles with dextran/chitosan shell and BSA/chitosan core—Doxorubicin loading and delivery
Qi, J., Yao, P., He, F., Yu, C., & Huang, C. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.063 · Cited by 215
McIntosh, D. P., Tan, X.-Y., Oh, P., & Schnitzer, J. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251662398 · Cited by 210
Nigam, P., Waghmode, S., Louis, M., Wangnoo, S., Chavan, P., & Sarkar, D. (2014) · J. Mater. Chem. B · doi:10.1039/c4tb00015c · Cited by 194
Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles
Mishra, V., Mahor, S., Rawat, A., Gupta, P. N., Dubey, P., Khatri, K., & Vyas, S. P. (2006) · Journal of Drug Targeting · doi:10.1080/10611860600612953 · Cited by 191
YANG, L., CUI, F., CUN, D., TAO, A., SHI, K., & LIN, W. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.03.028 · Cited by 190
Müller, C., Struthers, H., Winiger, C., Zhernosekov, K., & Schibli, R. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.107235 · Cited by 188
Albumin-Based Nanodevices as Drug Carriers
Loureiro, A., Azóia, N. G., Gomes, A. C., & Cavaco-Paulo, A. M. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160125114900 · Cited by 187
Van Woensel, M., Wauthoz, N., Rosière, R., Mathieu, V., Kiss, R., Lefranc, F., Steelant, B., Dilissen, E., Van Gool, S. W., Mathivet, T., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.032 · Cited by 166
Development of DNA Nanostructures for High-Affinity Binding to Human Serum Albumin
Lacroix, A., Edwardson, T. G. W., Hancock, M. A., Dore, M. D., & Sleiman, H. F. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b02917 · Cited by 164
Wagner, S., Rothweiler, F., Anhorn, M. G., Sauer, D., Riemann, I., Weiss, E. C., Katsen‐Globa, A., Michaelis, M., Cinatl, J. J., Schwartz, D., et al. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.093 · Cited by 162
Zhao, P., Yin, W., Wu, A., Tang, Y., Wang, J., Pan, Z., Lin, T., Zhang, M., Chen, B., Duan, Y., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201700403 · Cited by 160
Chatterjee, M., Ben‐Josef, E., Robb, R. N., Vedaie, M., Seum, S., Thirumoorthy, K., Palanichamy, K., Harbrecht, M. T., Chakravarti, A., & Williams, T. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0604 · Cited by 159
Anhorn, M. G., Wagner, S., Kreuter, J., Langer, K., & von Briesen, H. (2008) · Bioconjugate Chemistry · doi:10.1021/bc8002452 · Cited by 157
Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer
Choi, S. H., Byeon, H. J., Choi, J. S., Thao, L., Kim, I., Lee, E. S., Shin, B. S., Lee, K. C., & Youn, Y. S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.008 · Cited by 156
Khandelia, R., Bhandari, S., Pan, U. N., Ghosh, S. S., & Chattopadhyay, A. (2015) · Small · doi:10.1002/smll.201500216 · Cited by 156
Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review
Hauser, C. A., Stockler, M. R., & Tattersall, M. H. N. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0079-9 · Cited by 144
Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma
Suzuoki, M., Miyamoto, M., Kato, K., Hiraoka, K., Oshikiri, T., Nakakubo, Y., Fukunaga, A., Shichinohe, T., Shinohara, T., Itoh, T., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600619 · Cited by 142
Hidalgo, M. M., Plaza, C., Musteanu, M., Illei, P. B., Brachmann, C. B., Heise, C. C., Pierce, D. W., Lopez-Casas, P. P., Menéndez, C., Tabernero, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3222 · Cited by 141
Drug loading and release on tumor cells using silk fibroin–albumin nanoparticles as carriers
Subia, B., & Kundu, S. C. (2012) · Nanotechnology · doi:10.1088/0957-4484/24/3/035103 · Cited by 138
Rodríguez-Pinilla, S. M., Honrado, E., Hardisson, D., Benitez, J. J., & Palacios, J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9184-1 · Cited by 135
Sarett, S. M., Werfel, T. A., Lee, L., Jackson, M. A., Kilchrist, K. V., Brantley‐Sieders, D. M., & Duvall, C. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621240114 · Cited by 130
Self-citationTumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles
Wartlick, H., Spänkuch-Schmitt, B., Strebhardt, K., et al. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.01.029 · Cited by 123
Melder, R. J., Osborn, B. L., Riccobene, T. A., Kanakaraj, P., Wei, P., Chen, G., Stolow, D. T., Halpern, W., Migone, T., Wang, Q., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0624-7 · Cited by 113
Schmid, B., Chung, D., Warnecke, A., Fichtner, I., & Kratz, F. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0602735 · Cited by 112
Stork, R., Müller, D., & Kontermann, R. E. (2007) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm061 · Cited by 111
Caveolae as potential macromolecule trafficking compartments within alveolar epithelium
Gumbleton, M. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00142-9 · Cited by 110
Nanogels prepared by self‐assembly of oppositely charged globular proteins
Yu, S., Yao, P., Jiang, M., & Zhang, G. (2006) · Biopolymers · doi:10.1002/bip.20539 · Cited by 105
Xie, L., Tong, W., Yu, D.-H., Xu, J., Li, ., & Gao, C. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm16831f · Cited by 104
Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin
Unger, C., Häring, B., Medinger, M., Drevs, J., Steinbild, S., Kratz, F., & Mross, K. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2776 · Cited by 104
Warnecke, A., Fichtner, I., Garmann, D., Jaehde, U., & Kratz, F. (2004) · Bioconjugate Chemistry · doi:10.1021/bc049829j · Cited by 101
Abbasi, S. Q., Paul, A., Shao, W., & Prakash, S. (2011) · Journal of Drug Delivery · doi:10.1155/2012/686108 · Cited by 99
Petrova, N. S., Chernikov, I. V., Meschaninova, M. I., Dovydenko, I. S., Venyaminova, A. G., Аркадьевна, З. М., Vlassov, V. V., & Chernolovskaya, E. L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr1002 · Cited by 97
Orlova, A., Jonsson, A., Rosik, D., Lundqvist, H., Lindborg, M., Abrahmsén, L., Ekblad, C., Frejd, F. Y., & Максимилианович, Т. В. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.110700 · Cited by 92
New Strategy for the Extension of the Serum Half-Life of Antibody Fragments
Trüssel, S., Dumelin, C. E., Frey, K., Villa, A., Buller, F., & Neri, D. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9002772 · Cited by 89
Hartung, G., Stehle, G., Sinn, H., Wunder, A. P., Schrenk, H. H., Heeger, S., Kränzle, M., Edler, L., Frei, E., Fiebig, H., et al. (1999) · PubMed · Cited by 88
Hammarberg, B., Nygren, P., Holmgren, E., Elmblad, A., Tally, M., Hellman, U., Moks, T., & Uhlén, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.12.4367 · Cited by 87
In Vivo Labeling of Serum Albumin for PET
Niu, G., Lang, L., Kiesewetter, D. O., Ma, Y., Sun, Z., Guo, N., Guo, J., Wu, C., & Chen, X. S. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.139642 · Cited by 83
Li, R., Yang, H., Jia, D., Nie, Q., Cai, H., Fan, Q., Wan, L., Li, L., & Lu, X. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.004 · Cited by 82
Thermosensitive polymer-conjugated albumin nanospheres as thermal targeting anti-cancer drug carrier
Shen, Z., Wei, W., Zhao, Y., Ma, G., Dobashi, T., Maki, Y., Su, Z. G., & Wan, J. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.07.006 · Cited by 81
Chernikov, I. V., Gladkikh, D. V., Meschaninova, M. I., Venyaminova, A. G., Аркадьевна, З. М., Vlassov, V. V., & Chernolovskaya, E. L. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.011 · Cited by 81
Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery
Pichler, V., Mayr, J., Heffeter, P., Dömötör, O., Enyedy, E. A., Hermann, G., Groza, D., Köllensperger, G., Galanksi, M., Berger, W., et al. (2013) · Chemical Communications · doi:10.1039/c3cc39258a · Cited by 79
Jacobson, O., Kiesewetter, D. O., & Chen, X. S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00487 · Cited by 79
Floxuridine Homomeric Oligonucleotides “Hitchhike” with Albumin In Situ for Cancer Chemotherapy
Jin, C. Y., Zhang, H., Zou, J., Liu, Y., Zhang, L., Li, F., Wang, R., Xuan, W., Ye, M., & Tan, W. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201804156 · Cited by 78
Bolling, C., Graefe, T., Lübbing, C., Jankevičius, F., Uktveris, S., Česas, A., Meyer‐Moldenhauer, W., Starkmann, H., Weigel, M. T., Burk, K., et al. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-8221-6 · Cited by 77
Vis, A. N., van der Gaast, A., van Rhijn, B., Catsburg, T., Schmidt, C., & Mickisch, G. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-001-0417-z · Cited by 75
Chen, H., Wang, G., Lang, L., Jacobson, O., Kiesewetter, D. O., Liu, Y., Ma, Y., Zhang, X., Wu, H., Zhu, L., et al. (2015) · Theranostics · doi:10.7150/thno.14322 · Cited by 75
Chen, H., Jacobson, O., Niu, G., Weiss, I. D., Kiesewetter, D. O., Liu, Y., Ma, Y., Wu, H., & Chen, X. S. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.182097 · Cited by 75
Warnecke, A., & Kratz, F. (2003) · Bioconjugate Chemistry · doi:10.1021/bc0256289 · Cited by 74
Son, S., Song, S.-Y., Lee, S. J., Min, S., Kim, S. A., Yhee, J. Y., Huh, M. S., Kwon, I. C., Jeong, S. Y., Byun, Y., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.085 · Cited by 71
Sung, C., Nardelli, B., LaFleur, D. W., Blatter, E. E., Corcoran, M. L., Olsen, H. S., Birse, C. E., Pickeral, O. K., Zhang, J., Shah, D., et al. (2003) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900360520423 · Cited by 71
Pang, H., Braun, G. B., She, Z., Kotamraju, V. R., Sugahara, K. N., Teesalu, T., & Ruoslahti, E. I. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.12.006 · Cited by 69
Biodistribution and tumor imaging of an anti-CEA single-chain antibody–albumin fusion protein
Yazaki, P. J., Kassa, T., Cheung, C. W., Crow, D. M., Sherman, M. A., Bading, J. R., Anderson, A.-L. J., Colcher, D. M., & Raubitschek, A. A. (2008) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.10.010 · Cited by 69
Burger, A. M., Hartung, G., Stehle, G., Sinn, H., & Fiebig, H. (2001) · International Journal of Cancer · Cited by 68
Fiehn, C., Kratz, F., Sass, G., Müller-Ladner, U., & Neumann, E. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.086843 · Cited by 67
Zhang, Y., Ho, A. S. H., Yue, J., Kong, L., Zhou, Z., Wu, X., Yang, F., & Liang, H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.071 · Cited by 64
Gou, Y., Qi, J., Ajayi, J.-P., Zhang, Y., Zhou, Z., Wu, X., Yang, F., & Liang, H. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00314 · Cited by 64
Taheri, A., Dinarvand, R., Ahadi, F., Khorramizadeh, M. R., & Atyabi, F. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.033 · Cited by 63
Chung, S. W., Choi, J. U., Lee, B. S., Byun, J., Jeon, O., Kim, S. W., Kim, I.-S., Kim, S. Y., & Byun, Y. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.043 · Cited by 60
Isolation and characterization of a 14-kDa albumin-binding fragment of streptococcal protein G.
Sjöbring, U., Falkenberg, C., Nielsen, E., Åkerström, B., & Björck, L. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.5.1595 · Cited by 52
Malm, M., Bass, T. Z., Gudmundsdotter, L., Lord, M., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2014) · Biotechnology Journal · doi:10.1002/biot.201400009 · Cited by 52
Zhao, P., Yin, W., Wu, A., Tang, Y., Wang, J., Pan, Z., Lin, T., Zhang, M., Chen, B., Duan, Y., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910144 · Cited by 52
Hvam, M. L., Cai, Y., Dagnæs‐Hansen, F., Nielsen, J. S., Wengel, J., Kjems, J. K., & Howard, K. A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.009 · Cited by 49
Jiang, Y., Wong, S. M. S., Chen, F., Chang, T., Lu, H., & Stenzel, M. H. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00698 · Cited by 48
Lau, S., Graham, B., Cao, N., Boyd, B. J., Pouton, C. W., & White, P. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2002522 · Cited by 46
Choi, J., Hwang, H.-J., Shin, S. W., Choi, J., Um, S. H., & Oh, B. (2015) · Nanoscale · doi:10.1039/c5nr00211g · Cited by 41
Bieńk, K., Hvam, M. L., Pakula, M. M., Dagnæs‐Hansen, F., Wengel, J., Malle, B. M., Kragh‐Hansen, U., Cameron, J., Bukrinski, J. T., & Howard, K. A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.013 · Cited by 39
Marques, J., George, J. K., Smith, A. I., Bhakta, V., & Sheffield, W. P. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616148 · Cited by 33
Kuhlmann, M., Hamming, J. B. R., Voldum, A., Τσακιρίδου, Γ., Larsen, M. T., Schmøkel, J. S., Sohn, E., Bieńk, K., Schaffert, D., Sørensen, E. S., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.10.004 · Cited by 33
Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment
Liu, Y., Wang, G., Zhang, H., Ma, Y., Lang, L., Jacobson, O., Kiesewetter, D. O., Zhu, L., Gao, S., Ma, Q., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00625 · Cited by 30
“Albumin Hitchhiking” with an Evans Blue Analog for Cancer Theranostics
Ehlerding, E. B., Lan, X., & Cai, W. (2017) · Theranostics · doi:10.7150/thno.24183 · Cited by 29
Stefano, G. D., FIUME, L., Baglioni, M., Bolondi, L., Chieco, P., Kratz, F., Pariali, M., & Rubini, G. (2007) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.008 · Cited by 28
Su, T., Yang, H., Fan, Q., Jia, D., Tao, Z., Wan, L., & Lu, X. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.12.069 · Cited by 19
A Physiological Perspective on the Use of Imaging to Assess the In Vivo Delivery of Therapeutics
Qin, S., Fite, B. Z., Gagnon, M.-H., Seo, J. W., CURRY, F. E., Thorsen, F. A., & Ferrara, K. W. (2013) · Annals of Biomedical Engineering · doi:10.1007/s10439-013-0895-2 · Cited by 14
Cited by
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Spada, A., Emami, J., Tuszynski, J. A., & Lavasanifar, A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00046 · Cited by 591
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., & Cosco, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601626 · Cited by 571
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Natural biodegradable polymers based nano-formulations for drug delivery: A review
George, A., Shah, P. A., & Shrivastav, P. S. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.03.011 · Cited by 548
Recent trends in protein and peptide-based biomaterials for advanced drug delivery
Varanko, A., Saha, S., & Chilkoti, A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.008 · Cited by 369
Metadata
- Authors
- Hoogenboezem, E. N., & Duvall, C. L.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 130
- Pages
- 73-89
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2883860383
- Cited by
- 610
- References
- 130
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.